Understand the cost
Long-form guides
Twelve pieces on how GLP-1 pricing actually works — what a year costs, why flat and tiered pricing diverge, how to check a pharmacy before you pay, and where the advertised number stops describing what you are charged.
What a year of compounded tirzepatide actually costs
The full-year arithmetic for compounded tirzepatide across every rankable US program, and the four things that move the number.
Flat versus dose-tiered pricing, over a titration year
Why two programs advertising the same price can cost hundreds apart over a titration year, with worked examples from the database.
How to check a compounding pharmacy before you pay
Six checks that establish who actually makes your compounded GLP-1, under what licence, with what inspection history.
Start price versus maintenance price
Why the advertised GLP-1 price and your third invoice differ, and how to read past a 'from' figure.
Compounded tirzepatide versus Zepbound
The cash-price gap between compounded tirzepatide and the approved product, and what sits inside that gap.
Which compounded tirzepatide programs still have a lawful lane
What changed when the shortages were resolved, what 503A compounding still permits, and how to read a program's lane.
What a year of compounded semaglutide actually costs
Full-year compounded semaglutide costs across every rankable US program, and why the field is tighter than tirzepatide's.
Compounded semaglutide versus Wegovy
The cash-price gap, what the trial evidence does and does not cover, and the salt-form question.
Oral and sublingual compounded GLP-1s
What is actually being sold as needle-free GLP-1, why absorption is the open question, and why these are not price-ranked here.
Semaglutide dose ladder economics
What sixteen weeks of titration costs on flat versus tiered programs, and why long-term framing changes the maths.
The insurance door: coverage, prior authorisation and appeals
How to establish whether your plan covers a GLP-1, and the prior authorisation and appeal sequence when it denies.
How to read this database
What the five evidence statuses mean, why the gaps matter more than the numbers, and how to challenge a figure.
Tirzepatide dose ladder economics
What twenty weeks of tirzepatide titration costs on flat versus tiered programs, and the incentive problem tiering creates.
Membership fees: the shadow price in GLP-1 programs
Who charges a membership, why it behaves worse than a higher medication price, and when it is actually defensible.
Prepaid plans: what the discount really costs
What twelve-month tirzepatide terms save, what you are betting on, and why refund policy and discount are one decision.
What 'all-inclusive' should have to mean
The five separable components of a GLP-1 purchase, a four-question test, and which programs unbundle nothing.
Switching GLP-1 providers without a gap
How to change tirzepatide providers without losing your titration position or your supply.
Why compounded tirzepatide costs what it does
The real cost structure behind compounded tirzepatide, how to read a price below the field floor, and what the brand premium buys.
The GLP-1 price war, measured
The same molecule at the same dose spans hundreds of dollars a month across US programs. The spread, what drives it, and how to use it.
If your compounded GLP-1 program stops shipping
The plan to have ready before you need it: records, prepaid exposure, avoiding a gap, and choosing a replacement on disclosure.
Stopping a GLP-1, weight regain, and what it does to the maths
Trial evidence shows substantial regain after stopping, which makes the relevant cost an indefinite horizon rather than a year.